Measurable Goals for a Patient Admitted for Laparoscopic Cholecystectomy

PREOPERATIVE GOALS

• Patient will verbalize understanding of the procedure, expected sequence of events (NPO requirements, consent, anesthesia, recovery), and postoperative expectations before going to the OR.

• Patient will report anxiety at 3 or less on a 0-10 scale after preoperative teaching and nurse-patient interaction.

• Sequential compression devices (SCDs) are applied and functioning before induction of anesthesia per protocol, given the laparoscopic approach requires steep reverse-Trendelenburg positioning which increases DVT risk. (Sleisenger & Fordtran's GI and Liver Disease)

• Prophylactic antibiotics are administered within 60 minutes before skin incision in patients with acute cholecystitis, cholangitis, advanced age, or long-standing symptoms. Not required for uncomplicated biliary colic. (Sleisenger & Fordtran's GI and Liver Disease)

IMMEDIATE POSTOPERATIVE GOALS (PACU / First 24 Hours)

• Patient will report pain at ≤4/10 on a numeric rating scale within 30 minutes of arrival to PACU, and ≤3/10 at rest by 2 hours post-op, using multimodal analgesia (NSAIDs, acetaminophen, local anesthetic port-site infiltration ± opioids as needed).
• Shoulder-tip pain from residual CO2 should be acknowledged and managed; patient will report this is tolerable by 4 hours post-op.

• Patient will report absence of nausea or rate it ≤2/10 within 1 hour of PACU arrival, using antiemetics as prescribed. PONV is especially relevant with laparoscopic procedures under general anesthesia. (Barash Clinical Anesthesia)

• Vital signs (BP, HR, SpO2 ≥95%, RR 12-20/min, temperature 36-37.5°C) remain within normal limits within 1 hour of surgery and throughout the postoperative period.
• Urine output ≥0.5 mL/kg/hr if catheterized.

• Patient is monitored for signs of:
  • Bile duct injury: persistent abdominal pain, fever, jaundice, raised bilirubin - absent at 24-hour assessment
  • Port-site bleeding: dressings dry and intact, abdomen soft and non-distending by 2 hours post-op
  • Surgical site infection (SSI): wound sites without erythema, swelling, or purulent discharge through discharge and follow-up

• Patient will sit up on the edge of the bed within 2-4 hours post-op and ambulate to the bathroom or hallway within 6-8 hours of surgery, if hemodynamically stable (supports early recovery and reduces DVT risk).

• Patient will tolerate clear fluids within 2-4 hours of return from OR; advance to light diet as tolerated by the evening of surgery day, consistent with ERAS (Enhanced Recovery After Surgery) principles. (Schwartz's Principles of Surgery)

• Patient will perform deep breathing exercises / incentive spirometry every 1-2 hours while awake to prevent atelectasis, with SpO2 maintained ≥95% on room air by 4 hours post-op.

DISCHARGE GOALS (Typically same day or next day)

• Patient will demonstrate pain at ≤3/10 at rest and ≤5/10 with activity, managed with oral analgesics (acetaminophen ± NSAIDs) before discharge.

• Patient tolerates a regular light diet and oral fluids without nausea or vomiting at time of discharge.

• Patient ambulates independently and safely on a flat surface before discharge.

• Patient (or caregiver) correctly verbalizes/demonstrates how to care for port-site wounds, including signs of infection (redness, swelling, purulent discharge, fever >38°C) that require medical attention, before discharge.

• Patient accurately states:
  • Activity restrictions (avoid heavy lifting >10 lbs for 1-2 weeks)
  • Dietary advice (low-fat diet initially, gradual return to normal)
  • When to seek medical care (fever, jaundice, increasing pain, bile-colored drainage)
  • Follow-up appointment details
  • before leaving the facility

• Patient is afebrile, has resolving (not worsening) abdominal tenderness, and is without jaundice or signs of bile leak at the time of discharge. (Sleisenger & Fordtran's GI and Liver Disease)

Summary Table

Measurable Goals as the Treating Physician - Laparoscopic Cholecystectomy

PREOPERATIVE GOALS

• Diagnosis confirmed by ultrasound (gallstones/cholecystitis with wall thickening, pericholecystic fluid, Murphy's sign)
• Absolute contraindications excluded: inability to tolerate GA, severe coagulopathy, end-stage liver disease with portal hypertension
• Relative contraindications (severe COPD, CHF, pulmonary hypertension) documented and risk-benefit assessed (Sabiston Textbook of Surgery)

• LFTs (bilirubin, ALP, ALT/AST), amylase/lipase reviewed
• If intermediate or high suspicion for CBD stones: MRCP or EUS performed and result documented before listing for surgery
• If choledocholithiasis confirmed preoperatively: ERCP with stone clearance arranged before or concurrent with cholecystectomy (Sabiston Textbook of Surgery)

• Anticoagulants bridged or withheld per protocol (e.g., warfarin stopped 5 days prior, INR <1.5 on day of surgery)
• Diabetic patients: fasting glucose <180 mg/dL on day of surgery; insulin regimen adjusted for NPO status
• Hypertension: BP <160/90 mmHg at time of admission
• Anemia: Hb >8 g/dL (elective); transfuse or defer if <8 g/dL with symptoms

• DVT risk assessed (Caprini score); chemical prophylaxis (LMWH) +/- mechanical (SCDs) prescribed before induction for moderate-high risk patients

• For uncomplicated biliary colic: no prophylaxis required
• For acute cholecystitis, cholangitis, advanced age, or long-standing disease: IV cephalosporin administered within 60 minutes of skin incision (Sleisenger & Fordtran's GI and Liver Disease)

• Patient counseled on: bile duct injury (0.14-0.5%), conversion to open (2-8%), wound infection, bleeding, bile leak, retained stones, post-cholecystectomy syndrome
• Consent signed and documented before premedication

INTRAOPERATIVE GOALS

• Two (and only two) structures confirmed entering the gallbladder - cystic duct and cystic artery
• Lower one-third of gallbladder dissected free from the cystic plate
• Hepatocystic triangle cleared of all fat and fibrous tissue
• CVS confirmed and documented (photo/video) before any clip is applied - this is the single most effective means of preventing bile duct injury (Current Surgical Therapy 14e)

• Indications: unclear anatomy, suspected CBD stone, history of pancreatitis, abnormal LFTs
• Cholangiogram obtained and interpreted correctly intraoperatively if any doubt exists about biliary anatomy (Sabiston Textbook of Surgery)

• Uncomplicated laparoscopic cholecystectomy completed in 60-90 minutes; if >2 hours with difficult anatomy, reassess need for conversion or subtotal cholecystectomy

• If CVS cannot be achieved safely (dense inflammation, bleeding, anatomical uncertainty): convert or perform subtotal cholecystectomy rather than persist; conversion is not failure - it is sound surgical judgment
• Conversion rate benchmark: <5% (elective), up to 20% acceptable in acute cholecystitis (Sleisenger & Fordtran's GI and Liver Disease)

• All spilled stones identified and retrieved; documented in operative note
• Failure to retrieve spilled stones is associated with late abscess and foreign body granuloma (Sabiston Textbook of Surgery)

POSTOPERATIVE GOALS

• Target: 0 bile duct injuries per procedure
• Benchmark: Population rate of 0.14-0.5%; institutional audit should aim for the lower end (Sleisenger & Fordtran's GI and Liver Disease)
• Early recognition: any patient with persistent pain, fever, jaundice, or rising bilirubin post-op must be investigated immediately (HIDA scan, MRCP, or CT abdomen)

• Prescribe paracetamol + NSAID as baseline; opioids only as rescue
• Target: patient comfortable at rest with NRS ≤3/10 by 4 hours post-op, managed without IV opioids in uncomplicated cases

• Patient tolerating oral fluids by 2-4 hours post-op; diet advanced to normal within 24 hours
• Consistent with ERAS principles: early nutrition reduces ileus and shortens LOS (Schwartz's Principles of Surgery)

• Discharge when: pain controlled on oral meds, tolerating diet, ambulating, afebrile, normal vitals, no evidence of complication
• Benchmark: Most elective laparoscopic cholecystectomy patients return to full activity within 1 week (Sleisenger & Fordtran's GI and Liver Disease)

• Target: 0 returns to theatre; <5% 30-day readmission rate
• Common causes to monitor and prevent: port-site bleeding, bile leak, retained CBD stone, SSI

• Bilirubin, ALP, ALT trending down toward normal by 48-72 hours post-op; failure to normalize warrants imaging to exclude CBD injury or retained stone

• All port sites inspected: dry, intact, no hematoma or bile staining
• Umbilical port (12 mm): fascia closed with absorbable suture - documented in operative note to prevent port-site hernia

DISCHARGE / FOLLOW-UP GOALS

• Gallbladder specimen sent for histology in all cases
• Result reviewed at follow-up: incidental gallbladder carcinoma occurs in ~1% of cholecystectomy specimens and requires re-staging/re-operation if found

• Outpatient review at 2 weeks: wound check, symptom review, histology result
• Persistent symptoms (diarrhea, dyspepsia, RUQ pain) investigated - post-cholecystectomy syndrome excluded; consider MRCP if LFTs abnormal

Summary: Physician Measurable Goals at a Glance